Marshall Wace, LLP
- SEC CIK
- 0001318757
- Latest filing
- Aug 13, 2026
ALNY holding history
Alnylam Pharmaceuticals, Inc. in every 13F filed by Marshall Wace, LLP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ALNY overviewAll 13F holders of ALNYFull Q2 2026 holdings
- Shares (Q2 2026)
- 259,799
- Value
- $78.2M
- % of portfolio
- 0.1%
- Quarters held
- 12
- Since Q3 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 259,799 | $78.2M | 0.1% | −839,519−76.4% | Reduced | Holders |
| Q1 2026 | 1,099,318 | $363.7M | 0.4% | +549,396+99.9% | Added | Holders |
| Q4 2025 | 549,922 | $218.7M | 0.2% | +41,551+8.2% | Added | Holders |
| Q3 2025 | 508,371 | $231.8M | 0.3% | +269,798+113.1% | Added | Holders |
| Q2 2025 | 238,573 | $77.8M | 0.1% | −30,359−11.3% | Reduced | Holders |
| Q1 2025 | 268,932 | $72.6M | 0.1% | −109,717−29.0% | Reduced | Holders |
| Q4 2024 | 378,649 | $89.1M | 0.1% | +315,182+496.6% | Added | Holders |
| Q3 2024 | 63,467 | $17.5M | <0.1% | +63,467 | New | Holders |
| Q1 2024 | 0 | $0 | 0.0% | −1,300−100.0% | Sold out | Holders |
| Q4 2023 | 1,300 | $248.8K | <0.1% | +1,300 | New | Holders |
| Q3 2023 | 0 | $0 | 0.0% | −11,085−100.0% | Sold out | Holders |
| Q2 2023 | 11,085 | $2.11M | <0.1% | +11,085 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −165,292−100.0% | Sold out | Holders |
| Q2 2022 | 165,292 | $24.1M | 0.1% | +165,292 | New | Holders |
| Q4 2021 | 0 | $0 | 0.0% | −16,427−100.0% | Sold out | Holders |
| Q3 2021 | 16,427 | $3.10M | <0.1% | +16,427 | New | Holders |